SUCCESSOR-2

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

What's the purpose of the trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide when combined with approved treatments carfilzomib and dexamethasone compared to approved treatments carfilzomib and dexamethasone alone in participants with relapsed and refractory multiple myeloma.

Trial status

Accepting patients

Phase
Phase 3
Enrollment
525
Last Updated
1 week ago
Patient Screener

Participating Centers

There are 20 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Carfilzomib
  • Dexamethasone
  • Mezigdomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Mezigdomide + Carfilzomib + Dexamethasone

Accepting patients

Carfilzomib + Dexamethasone

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.